L, L., J, Z., J, H., Y, G., Z, Z., Y, C., . . . M, C. (2025). Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. ImmunoTargets and Therapy, 14(Issue 1), 1187-1200.
Chicago-Zitierstil (17. Ausg.)L, Liang, et al. "Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study." ImmunoTargets and Therapy 14, no. Issue 1 (2025): 1187-1200.
MLA-Zitierstil (9. Ausg.)L, Liang, et al. "Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study." ImmunoTargets and Therapy, vol. 14, no. Issue 1, 2025, pp. 1187-1200.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.